

RealRate

## PHARMACEUTICAL 2020

## JOHNSON & JOHNSON Rank 49 of 362

Johnson Johnson

Selling, General and Research and Cost of Goods Intangible Assets, Other Expenses Administrative Development Sold Current Assets 30.6% Expense 131% -68.2% -30.5% 39.8% 56.2% 56.2% 131% 30.6% 39.8% -68.2% -30.5% Liabilities, Other Liabilities, Expenses Revenues Assets Liabilities Non-Current Current 149% 173% -8.37% 8.26% -10.5% -28.4% 149% 173% 8.26% -10.5% -28.4% Net Income Liabilities -16.2% 318% -30.4% 318% -19.2% 6.73% Comprehensive Stockholders Net Income -9.37% Equity 315% -35.4% -35.4% 315% Economic Capital Ratio 401%



## PHARMACEUTICAL 2020



## JOHNSON & JOHNSON Rank 49 of 362

Johnson Johnson

The relative strengths and weaknesses of JOHNSON & JOHNSON are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of JOHNSON & JOHNSON compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 318% points. The greatest weakness of JOHNSON & JOHNSON is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 68% points.

The company's Economic Capital Ratio, given in the ranking table, is 98%, being 401% points above the market average of -303%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 45,274,000        |
| Cost of Goods Sold                          | 27,556,000        |
| Intangible Assets                           | 81,282,000        |
| Liabilities, Current                        | 35,964,000        |
| Liabilities, Non-Current                    | 38,228,000        |
| Other Assets                                | 13,514,000        |
| Other Compr. Net Income                     | -669,000          |
| Other Expenses                              | 3,683,000         |
| Other Liabilities                           | 24,065,000        |
| Other Net Income                            | -2,168,000        |
| Property and Equipment                      | 17,658,000        |
| Research and Development                    | 11,355,000        |
| Revenues                                    | 82,059,000        |
| Selling, General and Administrative Expense | 22,178,000        |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 157,728,000       |
| Liabilities              | 98,257,000        |
| Expenses                 | 64,772,000        |
| Stockholders Equity      | 59,471,000        |
| Net Income               | 15,119,000        |
| Comprehensive Net Income | 14,784,500        |
| Economic Capital Ratio   | 98%               |